June 12, 2025 — Shanghai Escugen Biotechnology Co., Ltd. and Sovran Bio, Inc. jointly announced today the signing of a strategic collaboration agreement. This collaboration aims to leverage Sovran's novel approach to broad-spectrum disease targeting and unique biologic architectures together with Escugen's proprietary EZWi-Fit^® platform technology and deep development expertise to rapidly advance multiple novel antibody and antiody-drug conjugate (ADC) therapeutic product candidates to the clinical. Under the agreement, the parties will jointly contribute to partnered program research and development with shared upside.

On June 4, 2025, the Phase I clinical study (ESG406-101) of the ADC drug ESG406, independently developed by Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen"), successfully administered the first dose to a participant. ESG406 received approval from the National Medical Products Administration on April 21, 2025, to conduct clinical research. The initiation of the ESG406-101 project marks the comprehensive iteration and upgrade of Escugen 's ADC technology. Moving forward, the company will focus on the pipeline development of the new generation of ADC technologies.